Tammuella Chrisentery-Singleton
Pediatric Hematology-Oncology · New Orleans, LANPI 1710900758
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $913,669 of the $1,444,733 with a category attached, or 63.2%. It is spread thinly across 31 manufacturers, the largest accounting for just 23.1%. Among pediatric hematology-oncology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,128 payments — averaging $1280.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$333K
- Genentech USA, Inc.$259K
- HEMA Biologics, LLC$165K
- CSL Behring$150K
- Sanofi$137K
- Shire North American Group Inc$121K
- plus $279K from 25 others
Across 255 payments — averaging $2895.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$470K
- Pfizer$109K
- Kedrion Biopharma, Inc.$102K
- Novo Nordisk AS$24K
- HEMA Biologics, LLC$14K
- F. Hoffmann-la Roche AG$11K
- plus $8K from 2 others
What the payments were for
- Consulting fees$310,59621%
- Speaking & faculty fees$913,66963%
- Travel & lodging$197,89914%
- Food & beverage$22,4042%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 185 | $333,254 |
| Genentech USA, Inc. | 162 | $258,971 |
| HEMA Biologics, LLC | 180 | $165,111 |
| CSL Behring | 110 | $150,428 |
| Sanofi | 81 | $136,949 |
| Shire North American Group Inc | 126 | $121,332 |
| Biomarin Pharmaceutical Inc. | 69 | $64,794 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $48,540 |
| Pfizer | 13 | $31,004 |
| Kedrion Biopharma, Inc. | 14 | $29,876 |
| Octapharma USA, Inc. | 42 | $26,917 |
| Global Blood Therapeutics, Inc. | 37 | $19,022 |
| Kedrion Biopharma Inc. | 4 | $16,100 |
| F. Hoffmann-la Roche AG | 4 | $15,612 |
| Spark Therapeutics, Inc. | 13 | $12,594 |
| Novo Nordisk Health Care AG | 6 | $6,133 |
| Bioverativ Therapeutics Inc. | 1 | $3,842 |
| Grifols USA, LLC | 1 | $2,800 |
| Genentech, Inc. | 13 | $896 |
| Bayer | 7 | $167 |
| Viiv Healthcare Company | 1 | $105 |
| Novartis | 3 | $58 |
| Medexus Pharma, Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| USWM, LLC | 1 | $27 |
| Amgen | 1 | $23 |
| Duchesnay USA Incorporated | 1 | $22 |
| AstraZeneca | 1 | $22 |
| Day One Biopharmaceuticals | 1 | $19 |
| Chiesi USA, Inc. | 1 | $13 |
| Emmaus Medical, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMLIBRA$256,677
- SevenFact$160,611
- ADVATE$147,661
- HEMGENIX$98,771
- Esperoct$85,930
- Idelvion$63,387
- REBINYN$59,959
- ALTUVIIIO$51,355
- QFITLIA$49,698
- KOATE$30,475
- Albuked$25,275
- GAMMAKED$25,275
- KEDRAB$25,275
- RhoGAM Ultra-Filtered PLUS$25,275
- Afstyla$18,317
- NovoSeven$15,637
- Non-Covered Product$15,612
- Coagadex$15,423
- OXBRYTA$14,537
- NUWIQ$14,171
How this compares
$1,444,733 in reported general payments places this provider in the 95th percentile of 26 pediatric hematology-oncology providers in Louisiana.
See all pediatric hematology-oncology providers in Louisiana →
Other pediatric hematology-oncology in New Orleans
- Maria Velez-YanguasNew Orleans$105K
- Zachary LeblancNew Orleans$55K
- Dana LeblancNew Orleans$25K
- Renee GardnerNew Orleans$25K
- Pinki PrasadNew Orleans$20K
- Robert VasquezNew Orleans$6K
- Lolie YuNew Orleans$3K
- Craig LottermanNew Orleans$3K
- Cori MorrisonNew Orleans$1K
- Justin FargeNew Orleans$797
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.